Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972686 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study of GSK2126458
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT00972686 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 79 participants.
The verdict
NCT00972686, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory malignancy. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.
Interventions
- DRUG GSK2126458
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2009-08-31 |
| Est. Completion | 2015-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972686
The ClinicalTrials.gov registry entry for NCT00972686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK2126458 is the first listed.
NCT00972686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972686 about?
NCT00972686 is a clinical study titled "Dose-Escalation Study of GSK2126458". P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory malignancy. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of c...
What is the current status of trial NCT00972686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2009-08-31. Estimated completion is 2015-03-31.
What interventions are being tested in trial NCT00972686?
The interventions under investigation include: GSK2126458 (DRUG).
Who is sponsoring clinical trial NCT00972686?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.